VJHemOnc is committed to improving our service to you

ASH 2014 | ASH 2014: Phase III Lyma trial of rituximab maintenance after ASCT in mantle cell lymphoma

VJHemOnc is committed to improving our service to you

Bertrand Coiffier

At the 2014 American Society of Hematology (ASH) Annual Meeting, Prof Bertrand Coiffier (Centre Hospitalier Lyon-Sud, Pierre-Benite, France) discusses the first interim analysis of the phase III prospective Lyma study of rituximab maintenance versus wait and watch after four courses of rituximab, dexamethasone, cytarabine and cisplatin (R-DHAP) followed by autologous stem cell transplantation (ASCT) in previously untreated young patients (under 66 years old) with mantle cell lymphom

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter